Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Medical Device Network on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...
MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...
Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide ...
Zacks Investment Research on MSN
NTRA's Signatera secures PMDA approval for MRD testing in CRC in Japan
Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack ...
A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy. After undergoing treatment — including a stem ...
Natera recently announced that its Signatera minimal residual disease (MRD) test received approval from Japan’s Pharmaceuticals and Medical Devices Agency for use in colorectal cancer patients in the ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results